Outlook Therapeutics (OTLK)
Develops and commercializes ophthalmic bevacizumab for wet age-related macular degeneration.
Something off on this page? Send us feedback.
LYTENAVA is a purpose-built ophthalmic formulation of bevacizumab for wet AMD. The company develops and commercializes the product across authorized markets, with its current business concentrated on a single retina-focused therapy.
Develops and commercializes LYTENAVA, a purpose-built ophthalmic formulation of bevacizumab for wet age-related macular degeneration. The current business is concentrated on this product for retinal indications.
Marketing authorization arrived in the European Union and United Kingdom in 2024, followed by FDA approval for wet AMD in the United States in July 2026. Commercial launch had commenced in Germany, Austria, and the United Kingdom as of the FDA announcement.
Outlook Therapeutics evolved from Oncobiologics, which previously pursued broader monoclonal-antibody biosimilars in immunology and oncology. Commercialization is shaped by regulatory authorization and execution for LYTENAVA across approved markets.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | H.C. Wainwright | Reiterate | Neutral | $1 | $1.60 | |
| Jul 27, 2026 | BTIG | Upgrade | Neutral | Buy | $4 | |
| May 18, 2026 | BTIG | Downgrade | Buy | Neutral | ||
| Jan 2, 2026 | Chardan Capital | Target | $1 | |||
| Aug 29, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.2M · Total debt $18.4M · Total assets $26.2M · Shareholders' equity −$10.4M
- Revenue
- $9.0K
- Operating income
- −$10.8M
- Net income
- −$20.3M
No dividends on record.
| Institutions59 holders · as of Mar 31, 2026 | 8.87% | 10.73M shares | |
| Insiders6 holders · as of Aug 14, 2026 | 0.81% | 974.9K shares | |
| Otherremainder | 90.32% | 109.16M shares |
120.86M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (120.86M in the company's Sep 3, 2026 report, 187.00M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCInstitution | 3.45% | 4.17M | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 1.63% | 1.97M | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.50% | 603,606 | 13Fas of Mar 31, 2026 |
Gilpin Wealth Management, LLCInstitution | 0.50% | 600,162 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 0.40% | 477,471 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Robert Charles Jahr | director, officer: Chief Executive Officer | +303,030 | $1.05 |
| Aug 12, 2026 | Ghiath M. Sukhtian | director, 10 percent owner: | +5,050,504 | $1.05 |
| Aug 14, 2026 | Lawrence A. Kenyon | director, officer: Chief Financial Officer | +202,020 | $1.05 |
| Jul 29, 2026 | Faisal Ghiath Sukhtian | director | +95,398 | $1.05 |
| Jun 2, 2026 | Yezan Munther Haddadin | director | +29,000 | $0.8326 |
- Regeneron
Established anti-VEGF rival through EYLEA and EYLEA HD
- Novartis (ADR)
Anti-VEGF wet-AMD option through BEOVU
- Amgen
FDA-approved aflibercept biosimilar for wet AMD
- Harrow
U.S. commercializer of two ophthalmic anti-VEGF biosimilars
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Outlook Therapeutics | $0.6316 | +0.21% | $117.1M | — | — | — | −99.4% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Harrow | $38.98 | −0.06% | $1.46B | — | 31.7 | 5.3 | +10.9% |
| Median | 24.5 | 18.1 | 5.6 | +10.3% |